2nd Circ. On Hunt For Antitrust Theory In $2B Takeda Action
The fate of an antitrust action claiming spurious Takeda Pharmaceutical Co. patent claims cost diabetes patients $2 billion by delaying generic versions of Actos appeared to rest Friday on the Second...To view the full article, register now.
Already a subscriber? Click here to view full article